{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-055209","form_type":"8-K","ticker":"VKTX","cik":"0001607678","company_name":"Viking Therapeutics, Inc.","filed_at":"2023-10-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.761653+00:00","generated_at":"2026-06-09T10:48:43.728872+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Viking Q3 net loss $22.5M; cash $376M; obesity trial fully enrolled","bullets":["Net loss of $22.5M ($0.23/sh) vs $15.8M in Q3 2022; R&D expenses $18.4M, up from $12.0M.","Cash & equivalents $376M at Sept 30, 2023, vs $155.5M at Dec 31, 2022 (includes $287.5M public offering).","Phase 2 VENTURE trial of VK2735 (GLP-1/GIP agonist) for obesity fully enrolled (n=176); results expected 1H24.","Phase 1 oral VK2735 study ongoing; data expected 1Q24. Phase 2b VOYAGE (VK2809 for NASH) histology results expected 1H24.","Phase 1b VK0214 for X-ALD enrolling; enrollment completion expected 4Q23."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-055209","json":"https://secwatch.observer/filing/0000950170-23-055209.json","markdown":"https://secwatch.observer/filing/0000950170-23-055209.md","text":"https://secwatch.observer/filing/0000950170-23-055209.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1607678/000095017023055209/0000950170-23-055209-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1607678/000095017023055209/vktx-20231025.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T10:48:43.728872+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}